contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


transactions-in-zealand-pharma-shares-andor-related-securities-by-persons-discharging-managerial-responsibilities-andor-their-closely-associated-persons-48

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Zealand Pharma er aktiv inden for bioteknologi. Særligt fokus findes på udviklingen af ​​lægemidler til behandling af diabetes og forskellige tarmsygdomme. Virksomheden har en varieret produktportefølje med separate mærker, der sælges på globalt plan. Den største forretning er på det nordiske marked. Zealand Pharma blev grundlagt i 1997 og har hovedkontor i Søborg.

Zealand Pharma

Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons...

Company announcement – No. 24 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, December 5, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit <a href="https://www.globenewswire.com/Tracker?data=eheHz6T2ntWJpI4knwaEorepV0hum5Y_MoT_v_EfDscYYVGuhixanTpOZh3Q-dFka2ejm3hOYb9kTKe-c6vfKuTkxERpHmL-_omcsder2ZU=">www.zealandpharma.com</a>. Contact Adam Lange (Investors) Vice President, Investor Relations Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=0gaWSnUH6CAeI531U_cq_TwwfF7RYzjp97C9bQ6-dVOxImt4Kxklemv62qJb7UVLbe8FA0tuAimBRePy8ln7qtio1WMyjQI9EDOd2idcY1jcRBZ-w07upHAmeLxMJJc1">alange@zealandpharma.com</a> Neshat Ahmadi (Investors) Investor Relations Manager Zealand Pharma Email: <a href="https://www.globenewswire.com/Tracker?data=JlfAQCF7NTNa6OVEec27vrl8CsRiR93Em2hDrassdwhVb3DVpz7c4mXl11mhm8j1fgQfqu2SNWZRStv_Vw4aO6G0DAsym9bwTZDllowAnJ57_YPYfZ8dy-4RZgimnHNb">neahmadi@zealandpharma.com</a> Rachel James-Owens (Media) Vice President, Corporate Communications &amp; Media Relations Zealand Pharma <a href="https://www.globenewswire.com/Tracker?data=Oh5mHM5iCWQjI_PHgzuuhoNFGbLLSPGW6sHJftBU0i5_CulsST8BTGJNVIH4wmIfpAwr-CTvIBkXI210lPH1ZwUt2nlodAiyQyEbInfO8p7c8vWazgK-pMTxvQneLAKqh-2fXINSRgw0GBeUKRwQf3rHozWbELQ_Q2Cwn2dErHLrxHae0zyas8yxApLCULWqyUdEahQq8uwQmyow7zOysqt-wP3QLs5TkDTafmGvuge96PBE4vTbbSBaMAdaRvBaFiixji3B0k2Y6FcBcFNKaOvpEJEDrEzFoty4202sBpMzm9XyZrHrrRUO9vnMP0avQSCxb96_Pgzf3-ueXSwZ1FRf_pvXNfEKl-PYgHqbYo1cUu_vFXge1Q4pseRL67_I3dDQM6C633Ncr9km0Xu7n0pAZq00tJ505J_yxuUqD51I1cr7SoEj1KhMaC4R0qffvbjtiL8Jxbla3HvlZtX2st-njTpmtg4rrFlH4bvuTpJSQvlyHlglwlPTd8pc24bjf-4auCrolR1aCrfVa3Iu0zUc-cSFyb7GCPzaXrLJss5mhDhSINan4Xfw5ZNCj1kt">RJamesOwens@zealandpharma.com</a> Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/c6954f1f-e37c-4141-81af-a272bd8400a3">2025-12-05_PDMR notification Henriette Wennicke</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE0MzI0OCM0MDIyNzg0MjIjMjAwMTcwMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/MThmN2M3YjEtMWRmYS00ZjQ2LTk3MjgtNjcwM2I5OGE2NzFkLTEwMTMyNzQtMjAyNS0xMi0wNS1lbg==/tiny/Zealand-Pharma.png" alt="">

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons